ClinicalTrials.gg
RecruitingNCT07033169Updated Sep 28, 2026

A Skin Image Reference Tool to Aid Healthcare Providers' Diagnosis

An observational study in Dermatologic Disease, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Wake Forest University Health Sciences · Observational

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Sep 28, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
400
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.

Planned enrollment
13th of 28
400 · median 298
Started
2025
with 14 others
Observational
29 of 202
7 open now
Primary completion
2027-09
later than 28 of 48 live
Registered
187th of 202
by date

Among the 202 studies in Skin Diseases with a site in United States, this one is the 13th largest by planned enrollment of the 28 observational ones that give a count, is one of 15 that started in 2025, is one of 29 observational ones, reaches primary completion later than 28 of the 48 other live ones, and was the 187th registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 10 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Skin Diseases with a site in United States, or all of them as a file.
02

Study summary

Consented patients will have three images taken of their dermatologic conditions within the Belle.ai software. These images will be uploaded and saved within the Belle software system where a single AI-generated differential list will be generated based on the three photos. All photos uploaded will be de-identified. The software will not have any unique identifiers of participants saved in the system. The photos will be named based on participant enrollment numbers or unique code numbers and no unique identifiers will be attached to the photos. There will be no data collection form necessary for this study

Read the detailed description

Belle.ai provides a differential diagnosis from more than 2,000 different skin conditions leveraging a database trained on over 500,000 images. The image referencing technology deploys deep learning to analyze an uploaded clinical image and then matches its geometric pattern characteristics to Belle.ai's database of images to provide reference differentials. The purpose is to determine the validity of the Belle.ai software in diagnosing common dermatologic diseases across a range of skin tones.

Consented patients will have three images taken of their dermatologic disease within the Belle.ai software. These images will be uploaded and saved within the Belle system where a single AI-generated differential list will be generated based on the three photos. The study coordinator will review uploaded patient "cases" and assign the cases for review and adjudication to designated Dermatologic Review Committee (DRC) members within the Belle web portal. Successful validation will require >80% concordance between Belle.ai's primary working diagnosis (#1 on the differential) and our dermatology experts. A team of dermatology experts will then secondarily assess the concordance among the remaining diagnoses.

03

Conditions studied

  • Dermatologic Disease

Browse trials for

Keywords

  • artificial intelligence
  • skin diseases
  • dermatology
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Up to 400 participants will be recruited for this study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must present to an Advocate Health dermatology clinic
  • Patient must have the ability and willingness to provide and comply with study procedures and visits
  • Participant dermatologists must have access to the required technology (e.g., smartphone with internet access) and be capable of using it for the required image capture

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to comply with study procedures due to physical or mental health limitations (as assessed by study coordinator)
  • Pediatric, adolescent, and teen patients who present with dermatological conditions on their genitalia will not be included in the study (in support of patient privacy concerns).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient at Advocate Health dermatology clinic

    The study, subject recruitment, and analysis will be conducted within the Advocate Health system at Atrium Health Wake Forest Baptist (AHWFB) in Winston-Salem, NC. Recruiters for this study include Advocate Health dermatology attendings, fellows, and staff, who will capture images of patients presenting to Wake Forest Dermatology Clinics in Winston-Salem, NC.

06

What researchers measure

Primary outcomes

  1. concordance of Belle.ai diagnoses with physician diagnoses.

    The study coordinator will review uploaded patient "cases" and assign them for review and adjudication to designated Dermatologic Review Committee (DRC) members within the Belle web portal. The DRC will be comprised of 1-2 Advocate Health board-certified dermatologists from each of the Winston, Charlotte, and Midwest dermatology practices.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The images will be uploaded and saved within the Belle system where a single AI-generated differential list will be generated based on the three photos. The study coordinator will review uploaded patient "cases" and assign the cases for review and adjudication to designated Dermatologic Review Committee (DRC) members within the Belle web portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 54 observational studies under Skin Diseases, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 250. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jun 24, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: i•••@wakehealth.edu→i•••@advocatehealth.org. See the current contact
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Contact Study contact's phone or email changed: i•••@wakehealth.edu→i•••@advocatehealth.org. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07033169
Collaborators
BelleTorus Corporation
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Sep 15, 2025
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Irma M Richardson, MHA
Contact
irma.richardson@advocatehealth.org
336-716-2903
Lindsay C Strowd, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion